TALTZ (ixekizumab) injection

TALTZ is a prescription medicine used for the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and active non-radiographic axial spondyloarthritis. Brand name: TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval: 2016

TALTZ (ixekizumab) injection Price In India and Overseas
TALTZ (ixekizumab) injectio

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

TALTZ (ixekizumab) injectio

Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody.

TALTZ is a humanized interleukin-17A antagonist indicated for the treatment of:
• patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• adults with active psoriatic arthritis.
• adults with active ankylosing spondylitis.
• adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

In the United States, ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation. In the European Union it is indicated for the treatment of moderate-to-severe plaque psoriasis and as a second-line therapy for active psoriatic arthritis.

Drug (Brand / Generic): TALTZ / ixekizumab
Current Indications: plaque psoriasis
Marketed by:: Eli Lilly and Company
Approval Date: 2016

Dosage forms and strengths of TALTZ (ixekizumab) injection
Autoinjector
• Injection: 80 mg/mL solution in a single-dose prefilled autoinjector.
Prefilled Syringe
• Injection: 80 mg/mL solution in a single-dose prefilled syringe.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.